Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 14/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 14/20 | 1.00 |
| ▸ | BCL2A1 | Q16548 | 11/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | JAZZ PHARMACEUTICALS THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4714447-A1 | DRUG COMBINATIONS OF BCL-XL INHIBITORS FOR TREATMENT OF CANCER | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2026-01-08 | — | — | US | claimed |
| EP-3436002-B1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | PRESAGE BIOSCIENCES INC (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | claimed |
| US-20250302840-A1 | COMBINATION THERAPIES | JANSSEN-CILAG (FR) | 2025-10-02 | — | — | US | claimed |
| EP-4585273-A2 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-16 | — | — | EP | claimed |
| EP-4580628-A1 | COMBINATION THERAPIES USING PRMT5 INHIBITORS AND BCL-2 FAMILY INHIBITORS FOR THE TREATMENT OF CANCER | Mirati Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| CN-114790209-A | Optimized combinations and their use for the treatment of cancer and autoimmune diseases | 浙江导明医药科技有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-114786654-A | Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists | 密执安大学评议会 | 2022-07-22 | — | — | CN | claimed |
| WO-2022122667-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | CELLESTIA BIOTECH AG (CH) | 2022-06-16 | — | — | WO | claimed |
| EP-4008324-A1 | COMBINATIONS COMPRISING AN INHIBITOR OF AN ANTI-APOPTOTIC PROTEIN, SUCH AS BCL-2, BCL-XL, BCLW OR MCL-1, AND A NOTCH SIGNALING PATHWAY INHIBITOR FOR TREATING CANCER | Cellestia Biotech AG (CH) | 2022-06-08 | — | — | EP | claimed |
| US-20220162561-A1 | COMPOSITION FOR PROMOTING SECRETION OF EXTRACELLULAR VESICLES | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-26 | — | — | US | claimed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022061299-A1 | NON-INVASIVE FUNCTIONAL COMPANION ASSAYS FOR ONCOGENE TARGETED THERAPY FOR BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022061174-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2022061201-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108534-A1 | LIPOSOMAL FORMULATIONS OF BCL INHIBITORS | BCL2, BCL3, BCL2L1 | BCL2L1 3/4885BCL2 1/4885MCL1 8/4885 |
| US-20260007728-A1 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | BCL3, BCL9, BCL9L | BCL2L1 11/4885BCL2 17/4885MCL1 9/4885 |
| US-20250302840-A1 | COMBINATION THERAPIES | MEN1, MLLT1, BMI1 | BCL2L1 9/4885BCL2 11/4885MCL1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.